Eduardo Díaz-Rubio
MD, PhD
Professor of Medical Oncology; Former Head, Medical Oncology Department
👥Biography 个人简介
Eduardo Díaz-Rubio, MD, PhD is Professor of Medical Oncology at the Universidad Complutense de Madrid and long-serving Head of the Medical Oncology Department at Hospital Clínico San Carlos. He is one of the most influential European oncologists in the field of colorectal cancer and was instrumental in establishing oxaliplatin-based chemotherapy regimens as international standards of care for mCRC. Dr. Díaz-Rubio was a key contributor to the early European phase III trials of FOLFOX4 (oxaliplatin, fluorouracil, and leucovorin) in metastatic colorectal cancer, helping to establish this regimen as first-line standard therapy in Europe in the late 1990s and early 2000s. His work provided foundational evidence supporting oxaliplatin's role in both the metastatic and adjuvant settings, with lasting impact on global treatment guidelines. A founding figure in Spanish oncology, Dr. Díaz-Rubio was a key driver behind the formation and scientific productivity of the Spanish Cooperative Group for Gastrointestinal Cancer Therapy (TTD). He has published more than 400 peer-reviewed papers, served on the boards of leading European oncology organizations including ESMO, and has received numerous national and international honors for his lifelong contributions to cancer medicine.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FOLFOX4 as First-Line Therapy in Metastatic CRC
Co-led pivotal European phase III trials establishing FOLFOX4 as a first-line standard for metastatic colorectal cancer, demonstrating superior response rates and progression-free survival compared with de Gramont LV5FU2, which led to widespread international adoption of oxaliplatin-based therapy.
Oxaliplatin Clinical Development
Contributed to the clinical development of oxaliplatin through multiple pivotal trials as principal investigator, providing key evidence supporting oxaliplatin approval by the EMA and FDA in both metastatic and adjuvant colorectal cancer settings.
Spanish Cooperative Group Leadership in GI Oncology
Founding and leading member of the TTD (Tumores del Tracto Digestivo) cooperative group in Spain, which conducted multiple practice-shaping randomized controlled trials in colorectal, gastric, and pancreatic cancers.
Adjuvant Chemotherapy Standards in Colon Cancer
Contributed to the European evidence base for adjuvant FOLFOX4 in stage III colon cancer, supporting regulatory approvals and integration of oxaliplatin-based adjuvant therapy into European and international treatment guidelines.
Representative Works 代表性著作
Randomised Phase III Trial Comparing FOLFOX4 with LV5FU2 in Untreated Patients with Metastatic Colorectal Cancer
Annals of Oncology (2002)
Phase III trial demonstrating the superiority of FOLFOX4 over infusional fluorouracil/leucovorin (LV5FU2) in first-line metastatic colorectal cancer, a key study supporting oxaliplatin approval in this setting.
Phase III Study of Capecitabine plus Oxaliplatin (XELOX) vs Infusional Fluorouracil plus Oxaliplatin and Leucovorin (FOLFOX4) in Metastatic Colorectal Cancer
Journal of Clinical Oncology (2007)
Phase III non-inferiority trial establishing XELOX as an alternative to FOLFOX4 in mCRC, offering a more convenient oral fluoropyrimidine-based regimen with similar efficacy.
Bevacizumab Combined with Chemotherapy for the First-Line Treatment of Advanced Colorectal Cancer
Oncology (2010)
Review article synthesizing the clinical evidence for bevacizumab in combination with oxaliplatin- and irinotecan-based chemotherapy backbones in mCRC, with guidance on patient selection and treatment duration.
Adjuvant Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) in Stage II–III Colon Cancer: Efficacy Results from the Spanish TTD Group
Clinical & Translational Oncology (2008)
Spanish cooperative group data supporting adjuvant FOLFOX4 in high-risk stage II and stage III colon cancer, contributing to the European evidence base for adjuvant oxaliplatin-based therapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-05 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Eduardo Díaz-Rubio 的研究动态
Follow Eduardo Díaz-Rubio's research updates
留下邮箱，当我们发布与 Eduardo Díaz-Rubio（Hospital Clínico San Carlos, Universidad Complutense de Madrid）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment